Posted by Michael Wonder on 10 Mar 2022
Ronapreve: first COVID-19 therapeutic drug to get Medsafe's approval not effective against Omicron
10 March 2022 - The first new COVID-19 therapeutic drug to get Medsafe's approval demonstrates "significantly diminished potency" against Omicron.
Medsafe approved the COVID-19 drug Ronapreve in December 2021 and secured enough doses to treat 5,300 people. The medicine mimics the body’s natural defences for fighting disease and is given intravenously or as an injection.
It is funded for people with COVID-19 who have mild to moderate symptoms and are at high risk of progressing to severe disease.
